[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA45324A - Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique - Google Patents

Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique

Info

Publication number
MA45324A
MA45324A MA045324A MA45324A MA45324A MA 45324 A MA45324 A MA 45324A MA 045324 A MA045324 A MA 045324A MA 45324 A MA45324 A MA 45324A MA 45324 A MA45324 A MA 45324A
Authority
MA
Morocco
Prior art keywords
liv1
polytherapy
adc
chemotherapeutic agent
chemotherapeutic
Prior art date
Application number
MA045324A
Other languages
English (en)
Inventor
Ana Kostic
Fu Li
Django Sussman
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA45324A publication Critical patent/MA45324A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MA045324A 2016-03-15 Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique MA45324A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308639P 2016-03-15 2016-03-15
US201662317792P 2016-04-04 2016-04-04
US201662367510P 2016-07-27 2016-07-27

Publications (1)

Publication Number Publication Date
MA45324A true MA45324A (fr) 2019-01-23

Family

ID=59852409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045324A MA45324A (fr) 2016-03-15 Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique

Country Status (14)

Country Link
US (2) US11325980B2 (fr)
EP (1) EP3429626A4 (fr)
JP (3) JP2019508433A (fr)
KR (3) KR20230169462A (fr)
CN (1) CN108697801A (fr)
AU (2) AU2017235545A1 (fr)
BR (1) BR112018068129A2 (fr)
CA (1) CA3016485A1 (fr)
EA (1) EA201891968A1 (fr)
IL (1) IL261505A (fr)
MA (1) MA45324A (fr)
MX (2) MX2018010847A (fr)
SG (2) SG10201912908QA (fr)
WO (1) WO2017161007A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3156420T3 (pl) 2010-12-06 2019-08-30 Seattle Genetics, Inc. Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka
SG11202004751TA (en) * 2017-12-01 2020-06-29 Seattle Genetics Inc Humanized anti-liv1 antibodies for the treatment of breast cancer
MX2021005395A (es) * 2018-11-07 2021-09-14 Crispr Therapeutics Ag Terapia del cáncer con células inmunitarias anti-liv1.
TW202133887A (zh) 2019-12-09 2021-09-16 美商西健公司 使用liv1-adc及pd-1拮抗劑之組合療法
WO2022198231A1 (fr) 2021-03-18 2022-09-22 Seagen Inc. Libération sélective de médicament à partir de conjugués internalisés de composés biologiquement actifs
WO2024188339A1 (fr) * 2023-03-15 2024-09-19 浙江博锐生物制药有限公司 Anticorps anti-liv-1 et conjugué anticorps anti-liv-1-médicament, et leur utilisation pharmaceutique

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69228300T2 (de) 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2132500A1 (fr) 1994-09-20 1996-03-21 David Lockwood Manning Methodes pour predire l'evolution des tumeurs du sein
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JP4614472B2 (ja) 1996-10-31 2011-01-19 アボット・ラボラトリーズ 乳房の疾患の検出に有用な試薬および方法
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
WO1998034118A1 (fr) 1997-01-30 1998-08-06 Yale University Methodes diagnostiques et compositions basees sur la repartition de rad51
EP1027444A1 (fr) 1997-10-31 2000-08-16 Abbott Laboratories Reactifs et procedes utiles pour deceler les pathologies mammaires
WO1999025877A1 (fr) 1997-11-18 1999-05-27 Abbott Laboratories Reactifs et procedes utiles pour detecter des maladies de la poitrine
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
EP1105528A4 (fr) 1998-08-04 2002-09-04 Diadexus Inc Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter
EP1953229A3 (fr) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Gênes régulés du cancer du sein et du colôn métastatiques
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6762020B1 (en) 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
AU3458401A (en) 2000-01-25 2001-08-07 Genentech Inc. Compositions and methods for treatment of cancer
WO2001096372A2 (fr) 2000-06-13 2001-12-20 University College Cardiff Consultants Ltd Transporteurs de zinc
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1410013A4 (fr) 2001-06-21 2006-02-01 Millennium Pharm Inc Compositions, necessaires et methodes destines a l'identification, a l'evaluation, a la prevention et au traitement des cancers du sein et de l'ovaire
WO2003004989A2 (fr) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
PT1572087E (pt) 2002-03-08 2008-07-11 Pdl Biopharma Inc Anticorpos contra o antigénio de cancro tmeff2 e suas utilizações
EP1545613B9 (fr) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Conjugues d'auristatine et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
CN1849337A (zh) 2003-01-27 2006-10-18 比奥根艾迪克Ma公司 利用igsf9和liv－1的、用于治疗癌症的组合物及方法
WO2004067564A2 (fr) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions contre l'antgene cancereux liv-1 et leurs utilisations
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006124269A2 (fr) 2005-05-16 2006-11-23 Amgen Fremont Inc. Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles
CN101309933A (zh) * 2005-09-07 2008-11-19 米迪缪尼有限公司 毒素偶联的Eph受体抗体
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
BRPI0710616A2 (pt) 2006-04-13 2011-08-16 Novartis Vaccines & Diagnostic métodos para tratar, diagnosticar ou detectar cáncer
WO2008070593A2 (fr) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Agents se liantà des cibles variables et utilisations de ceux-ci
JP2010527916A (ja) 2007-04-23 2010-08-19 ワイス・エルエルシー Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
US20110166838A1 (en) 2008-06-16 2011-07-07 Sividon Diagnostics Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
US20110195995A1 (en) 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
WO2010069858A1 (fr) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20110165566A1 (en) 2009-07-09 2011-07-07 Wittliff James L Methods of optimizing treatment of breast cancer
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
PL3156420T3 (pl) 2010-12-06 2019-08-30 Seattle Genetics, Inc. Humanizowane przeciwciała przeciw liv-1 i ich stosowanie w leczeniu raka
WO2012125712A2 (fr) 2011-03-14 2012-09-20 Respira Health, Llc Système de classification des tumeurs du poumon pour fumeurs et anciens fumeurs.
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
CN104755497A (zh) * 2012-05-11 2015-07-01 梅里麦克制药股份有限公司 结合抗癌治疗剂的双特异性scfv轭合物的剂量和给药
DE202012006349U1 (de) 2012-07-03 2013-07-05 Schuster Engineering Gmbh Schiffsladeanordnung
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
WO2015002134A1 (fr) 2013-07-02 2015-01-08 公益財団法人がん研究会 Vaccin induisant une immunité cellulaire
JP6612738B2 (ja) 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
SG11202004751TA (en) * 2017-12-01 2020-06-29 Seattle Genetics Inc Humanized anti-liv1 antibodies for the treatment of breast cancer
MX2021005395A (es) 2018-11-07 2021-09-14 Crispr Therapeutics Ag Terapia del cáncer con células inmunitarias anti-liv1.
GB201908208D0 (en) 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent
TW202133887A (zh) 2019-12-09 2021-09-16 美商西健公司 使用liv1-adc及pd-1拮抗劑之組合療法

Also Published As

Publication number Publication date
CN108697801A (zh) 2018-10-23
AU2024201856A1 (en) 2024-04-11
US11325980B2 (en) 2022-05-10
EP3429626A4 (fr) 2020-05-06
KR20180121571A (ko) 2018-11-07
MX2018010847A (es) 2019-07-04
SG11201807526SA (en) 2018-09-27
US20230235083A1 (en) 2023-07-27
AU2017235545A1 (en) 2018-10-25
JP2019508433A (ja) 2019-03-28
US20190085091A1 (en) 2019-03-21
SG10201912908QA (en) 2020-02-27
WO2017161007A1 (fr) 2017-09-21
CA3016485A1 (fr) 2017-09-21
JP2022058676A (ja) 2022-04-12
BR112018068129A2 (pt) 2019-01-15
IL261505A (en) 2018-10-31
KR20220157515A (ko) 2022-11-29
EA201891968A1 (ru) 2019-02-28
KR20230169462A (ko) 2023-12-15
JP2024075639A (ja) 2024-06-04
MX2023008849A (es) 2023-08-15
EP3429626A1 (fr) 2019-01-23

Similar Documents

Publication Publication Date Title
DK3442972T3 (da) Bromdomænehæmmere
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
MA47676A (fr) Polythérapie
DK3471609T3 (da) Kvantitativ seismokardiografi
MA46285A (fr) Polythérapie
MA49921A (fr) Polythérapie
MA51576A (fr) Polythérapie
MA49905A (fr) Polyesteramines et polyesterquats
DK3296485T3 (da) Ståldrager
FR3049449B3 (fr) Brasero portatif
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
BR112016023299A2 (pt) Composto tricíclico e inibidor de jak
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3189050T3 (da) Antivirale midler og anvendelser deraf
DK3481826T3 (da) Tyrosinkinaseinhibitorer
ES1171308Y (es) Cuadra Transportable
UA34707S (uk) Всюдихід
DK3263133T3 (da) Pyridinonforbindelse og anvendelse deraf
MA45324A (fr) Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante
ES1149460Y (es) Hidrojardinera movil
DK3672967T3 (da) Azaindolylpyridon- og diazaindolylpyridonforbindelser
DK3476320T3 (da) Intramedullær fikseringsanordning
DK3366672T3 (da) Biphenylforbindelse og anvendelse deraf
FR3038344B1 (fr) Assemblage aubage utilisant un emboitement